Within RCC, bladder cancer, and NSCLC, next-generation PD-(L)1 combinations are reshaping treatment across all disease stages, and the magnitude of benefit, the relevant biomarkers, and the toxicity trade-offs differ substantially by tumor type and by setting.
This review summarizes immune resistance in NSCLC through a framework that distinguishes primary resistance from acquired resistance, and discusses mechanism-based biomarkers, translational correlates, and rational therapeutic strategies for overcoming resistance.
Bo Yuan, Wenzhi Deng, Juan Luo et al.· Frontiers in Immunology· 0 citations
This review summarizes established and emerging ICI-based regimens in lung cancer, mechanisms of resistance relevant to NSCLC and SCLC, biomarker integration for patient selection and monitoring, and future directions to optimize efficacy and safety through combinatory and alternative immunotherapeutic strategies.
Junyoung Park, Choong‐Hwan Kwak, Yu-Chan Chang et al.· Frontiers in Immunology· 0 citations
Current evidence supports PD-L1 as the most widely implemented biomarker, but no single factor adequately captures the biological and temporal heterogeneity of treatment response, so integrated, dynamic, and context-specific biomarker models are required to improve precision immuno-oncology.
Long-Hua Lu, Ze-Yang Zeng, Zi-Qi Guan et al.· Journal of Clinical Question· 0 citations
Mature randomized survival data, longer-term safety assessment, and biomarker development are needed to define optimal patient selection and the clinical role of PD-(L)1/VEGF bispecific antibodies in NSCLC.
Aleena Kuriakose, Salem Gogah, E. Beleva· Journal of Clinical Question...· 0 citations
This review examines the emerging data on envafolimab and discusses strategies to optimize its therapeutic impact, including combination regimens and personalized approaches.
M. Kciuk, D. Kołat, Katarzyna Wanke et al.· Frontiers in Immunology· 0 citations
Limited benefit in other cancer subsets highlights the need for biomarker discovery and optimization of therapeutic strategies, including addition of antibody-drug conjugates to ICIs, next-generation checkpoint modulation, personalized neoantigen vaccines, and engineered cellular immunotherapy.
Victor M. Samperio, Ruba Alchaikh Hassan, Aishwarya Ghonge et al.· Expert Opinion on Biological...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
